Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Dedifferentiated Carcinoma
Endometrial Endometrioid Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Uterine Corpus Carcinosarcoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Procedure: Echocardiography
Radiation: High-Dose-Rate Vaginal Cuff Brachytherapy
Procedure: Multigated Acquisition Scan
Drug: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Drug: Trastuzumab/Hyaluronidase-oysk

First Posted Date: 2022-02-25

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 525

Registration Number: NCT05256225

Locations: 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 369 locations

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Phase 2

Not yet recruiting

Conditions: Resectable Non-small Cell Lung Cancer

Interventions: Drug: AK112
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2022-02-21

Last Posted Date: 2022-02-21

Lead Sponsor: Akeso

Target Recruit Count: 30

Registration Number: NCT05247684

SMMART Adaptive Clinical Treatment (ACT) Trial

Early Phase 1

Withdrawn

Conditions: Advanced Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Advanced Prostate Carcinoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Breast Carcinoma
Stage IV Ovarian Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma

First Posted Date: 2022-02-14

Last Posted Date: 2024-01-23

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT05238831

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Phase 1

Conditions: Advanced Malignant Tumors

Interventions: Drug: AK104
Drug: AK117
Drug: Paclitaxel
Drug: Capecitabine tablets
Drug: Cisplatin
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Docetaxel
Drug: 5-FU

First Posted Date: 2022-02-11

Last Posted Date: 2022-08-11

Lead Sponsor: Akeso

Target Recruit Count: 130

Registration Number: NCT05235542

Locations: 🇨🇳
Shanghai Renji Hospital, Shanghai, China

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Phase 2

Withdrawn

Conditions: Unresectable Breast Carcinoma
Locally Advanced Breast Cancer
Metastatic Breast Cancer
PD-L1 Gene Mutation
Triple Negative Breast Cancer

Interventions: Drug: Nab-paclitaxel
Drug: Paclitaxel
Radiation: Radiation Therapy
Drug: Pembrolizumab

First Posted Date: 2022-02-10

Last Posted Date: 2022-12-06

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT05233696

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

Not Applicable

Conditions: Gastric Cancer

Interventions: Procedure: Comparing Hyperthermic Intraperitoneal Chemotherapy
Drug: Paclitaxel
Drug: S1

First Posted Date: 2022-02-08

Last Posted Date: 2022-02-08

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 180

Registration Number: NCT05228743

Locations: 🇨🇳
Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Phase 3

Active, not recruiting

Conditions: Metastatic Non-Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab/Vibostolimab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Pemetrexed
Biological: Pembrolizumab

First Posted Date: 2022-02-07

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 700

Registration Number: NCT05226598

Locations: 🇪🇸
Hospital Clinico San Carlos-Oncology Department ( Site 1107), Madrid, Spain
🇨🇳
Jilin Cancer Hospital-oncology department ( Site 2603), Changchun, Jilin, China
🇨🇳
Zhejiang Cancer Hospital-Oncology ( Site 2612), Hangzhou, Zhejiang, China

and more 146 locations